GEISINGER MEDICAL CENTER
- Type
- Teaching hospital
- Where
- POTTSVILLE, PA
- Medicare CCN
- 390006
- Received
- $1,179,005 in 238 records, 2019 ($738,887 general, $440,118 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Geisinger Medical Center Fuzzy (name and state)
- Business registration: Geisinger Medical Center Fuzzy (name and state)
- Business registration: Geisinger Medical Center Fuzzy (name and state)
- Business registration: GEISINGER MEDICAL CENTER Fuzzy (name and state)
- Business registration: GEISINGER MEDICAL CENTER Fuzzy (name and state)
- Business registration: GEISINGER MEDICAL CENTER, INC. Fuzzy (name and state)
- Nonprofit contractor: GEISINGER MEDICAL CENTER Fuzzy (name and state)
- Nonprofit: GEISINGER MEDICAL CENTER Fuzzy (name and state)
- Trademark owner: Geisinger Medical Center Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 76 | $738,887 |
| 2019 | Research payment | 162 | $440,118 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Consulting Fee | 9 | $587,933 |
| Research payment | 162 | $440,118 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 31 | $62,781 |
| Grant | 5 | $37,350 |
| Charitable Contribution | 3 | $35,422 |
| Space rental or facility fees (teaching hospital only) | 12 | $11,900 |
| Gift | 10 | $2,748 |
| Education | 1 | $328 |
| Food and Beverage | 1 | $275 |
| Royalty or License | 3 | $89 |
| Honoraria | 1 | $58 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $12,375 | Research payment | Cash or cash equivalent | GEISINGER2018MRIPR887923926Fielden | 2019 | |
| 2019-12-31 | Linvatec Corporation | $1,374 | Grant | In-kind items and services | HALL POWER Device, ORTHOPEDIC SURGERY | 2019 | |
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $1,022 | Charitable Contribution | In-kind items and services | 2019 | ||
| 2019-12-31 | Siemens Medical Solutions USA, Inc. | $586 | Research payment | Cash or cash equivalent | Geisinger2019MRIPR724Haggerty | 2019 | |
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $88 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-31 | Novo Nordisk AS | $72 | Research payment | In-kind items and services | NN9931-4296 | 2019 | |
| 2019-12-31 | Stryker Corporation | $0 | Gift | Cash or cash equivalent | NONE Device, NONE | 2019 | |
| 2019-12-23 | Novo Nordisk AS | $737 | Research payment | Cash or cash equivalent | EX9536-4388 | 2019 | |
| 2019-12-19 | Novo Nordisk AS | $3,247 | Research payment | Cash or cash equivalent | NN9931-4296 | 2019 | |
| 2019-12-19 | Novo Nordisk AS | $671 | Research payment | Cash or cash equivalent | NN9931-4296 | 2019 | |
| 2019-12-19 | Novo Nordisk AS | $380 | Research payment | Cash or cash equivalent | NN9931-4296 | 2019 | |
| 2019-12-19 | Novo Nordisk AS | $192 | Research payment | Cash or cash equivalent | EX9536-4388 | 2019 | |
| 2019-12-19 | BioFire Diagnostics, LLC | $13 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray BJI Pivotal Study | 2019 |
| 2019-12-18 | Luminex Molecular Diagnostics | $58 | Honoraria | In-kind items and services | Medical Supply, Product | 2019 | |
| 2019-12-17 | Medtronic MiniMed, Inc. | $11,976 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Minimed 670G System Device, Durable Pump | 2019 | |
| 2019-12-17 | BioFire Diagnostics, LLC | $3,727 | Research payment | Cash or cash equivalent | FilmArray System Device, Clinical Diagnostics | FilmArray BJI Pivotal Study | 2019 |
| 2019-12-17 | Medical Device Business Services, Inc. | $2,976 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-12-17 | Insulet Corporation | $704 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (10 payments) | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2019 | |
| 2019-12-16 | Novo Nordisk AS | $24 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-12-10 | CSL Behring | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-12-09 | Merck Sharp & Dohme LLC | $6 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | PEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR | 2019 |
| 2019-12-05 | CSL Behring | $285 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-12-03 | Novo Nordisk AS | $2,250 | Research payment | Cash or cash equivalent | EX9536-4388 | 2019 | |
| 2019-11-30 | Novo Nordisk AS | $72 | Research payment | In-kind items and services | NN9931-4296 | 2019 | |
| 2019-11-29 | Novo Nordisk Inc | $50,000 | Research payment | Cash or cash equivalent | Decade plus,What relationship b/n longterm weight maint, clinical relevance&healthcare utilization? | 2019 | |
| 2019-11-26 | Oticon Medical, LLC | $328 | Education (14 payments) | Cash or cash equivalent | PONTO BONE ANCHORED HEARING SYSTEM Device, Medical Device | 2019 | |
| 2019-11-22 | Merck Sharp & Dohme LLC | $5,000 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-11-21 | Insulet Corporation | $352 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (10 payments) | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2019 | |
| 2019-11-19 | Roche Diagnostics Corporation | $600 | Consulting Fee | Cash or cash equivalent | CD cobas Automation Device, Centralized Diagnostics | 2019 | |
| 2019-11-15 | Covidien LP | $20,000 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-11-14 | Janssen Pharmaceuticals, Inc | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | INVOKANA Drug, Cardiovascular & Metabolism | 2019 | |
| 2019-11-11 | BioFire Diagnostics, LLC | $9,000 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray BJI Pivotal Study | 2019 |
| 2019-11-11 | BioFire Diagnostics, LLC | $3,869 | Research payment | Cash or cash equivalent | FilmArray System Device, Clinical Diagnostics | FilmArray BJI Pivotal Study | 2019 |
| 2019-11-07 | CSL Behring | $2,366 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-11-07 | CSL Behring | $1,403 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-11-07 | CSL Behring | $150 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-11-07 | CSL Behring | $50 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-11-06 | KARL STORZ Endoscopy-America | $690 | Gift | In-kind items and services | TELESCOPE,HOPKINS II,AUTOCLAV, Device, UROLOGY | 2019 | |
| 2019-11-06 | Insulet Corporation | $352 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (10 payments) | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2019 | |
| 2019-11-06 | KARL STORZ Endoscopy-America | $30 | Gift | In-kind items and services | TELESCOPE, HOPKINS II, 0', 4MM DIAMETER Device, ENT | 2019 | |
| 2019-11-06 | KARL STORZ Endoscopy-America | $30 | Gift | In-kind items and services | TELESCOPE,HOPKINS II FWD OBLG Device, GYNECOLOGY | 2019 | |
| 2019-11-01 | Merck Sharp & Dohme LLC | $178,765 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-10-31 | Novo Nordisk AS | $72 | Research payment | In-kind items and services | NN9931-4296 | 2019 | |
| 2019-10-29 | OpGen, Inc. | $15,000 | Research payment | Cash or cash equivalent | Acuitas AMR Gene Panel Urine Clinical Performance Evaluation | 2019 | |
| 2019-10-29 | Novo Nordisk AS | $3,081 | Research payment | Cash or cash equivalent | EX9536-4388 | 2019 | |
| 2019-10-29 | Novo Nordisk AS | $1,540 | Research payment | Cash or cash equivalent | NN9931-4296 | 2019 | |
| 2019-10-24 | BioFire Diagnostics, LLC | $2,242 | Research payment | Cash or cash equivalent | FilmArray System Device, Clinical Diagnostics | FilmArray BJI Pivotal Study | 2019 |
| 2019-10-24 | CSL Behring | $400 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-10-24 | Insulet Corporation | $352 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (10 payments) | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2019 | |
| 2019-10-22 | BioFire Diagnostics, LLC | $9,036 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray BJI Pivotal Study | 2019 |
| 2019-10-10 | CSL Behring | $8,842 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-10-10 | CSL Behring | $1,123 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-10-10 | CSL Behring | $50 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-10-09 | Stryker Corporation | $429 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-09 | Stryker Corporation | $175 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-09 | Stryker Corporation | $42 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-09 | Stryker Corporation | $17 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-03 | Endologix LLC | $20,875 | Research payment | Cash or cash equivalent | AFX Device, Cardiology/Vascular Diseases | LEOPARD | 2019 |
| 2019-10-03 | Novo Nordisk AS | $3,247 | Research payment | Cash or cash equivalent | NN9931-4296 | 2019 | |
| 2019-10-03 | Novo Nordisk AS | $380 | Research payment | Cash or cash equivalent | NN9931-4296 | 2019 | |
| 2019-10-01 | BioFire Diagnostics, LLC | $4,500 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray BJI Pivotal Study | 2019 |
| 2019-10-01 | BioFire Diagnostics, LLC | $4,500 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray BJI Pivotal Study | 2019 |
| 2019-10-01 | Insulet Corporation | $352 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (10 payments) | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2019 | |
| 2019-10-01 | Novo Nordisk AS | $75 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-09-30 | Medtronic Vascular, Inc. | $86 | Research payment | In-kind items and services | ECG Belt | 2019 | |
| 2019-09-30 | Novo Nordisk AS | $72 | Research payment | In-kind items and services | NN9931-4296 | 2019 | |
| 2019-09-26 | Novo Nordisk AS | $2,233 | Research payment | Cash or cash equivalent | NN9931-4296 | 2019 | |
| 2019-09-26 | Novo Nordisk AS | $737 | Research payment | Cash or cash equivalent | EX9536-4388 | 2019 | |
| 2019-09-25 | Medtronic MiniMed, Inc. | $17,415 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Minimed 670G System Device, Durable Pump | 2019 | |
| 2019-09-18 | Masimo Corporation | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SET and rainbow SET Device, Devices | 2019 | |
| 2019-09-17 | CSL Behring | $5,585 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-09-17 | CSL Behring | $50 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-09-10 | E.R. Squibb & Sons, L.L.C. | $151 | Research payment | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | Phase III VTE Prev in Children w ALL | 2019 |
| 2019-09-06 | Novo Nordisk AS | $24 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-08-31 | Novo Nordisk AS | $72 | Research payment | In-kind items and services | NN9931-4296 | 2019 | |
| 2019-08-30 | Novo Nordisk AS | $2,425 | Research payment | Cash or cash equivalent | NN9931-4296 | 2019 | |
| 2019-08-30 | Novo Nordisk AS | $691 | Research payment | Cash or cash equivalent | EX9536-4388 | 2019 | |
| 2019-08-30 | Novo Nordisk AS | $380 | Research payment | Cash or cash equivalent | NN9931-4296 | 2019 | |
| 2019-08-27 | Roche Diagnostics Corporation | $7,900 | Consulting Fee | Cash or cash equivalent | CD cobas Automation Device, Centralized Diagnostics | 2019 | |
| 2019-08-22 | CSL Behring | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-08-22 | Ethicon US, LLC | $350 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | DERMABOND Portfolio Device, Wound Closure | 2019 | |
| 2019-08-13 | CSL Behring | $18,605 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-08-13 | Novo Nordisk AS | $3,247 | Research payment | Cash or cash equivalent | NN9931-4296 | 2019 | |
| 2019-08-13 | CSL Behring | $550 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-08-13 | Novo Nordisk AS | $380 | Research payment | Cash or cash equivalent | NN9931-4296 | 2019 | |
| 2019-08-08 | Merck Sharp & Dohme LLC | $38 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | PEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $35 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | PEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $20 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $3 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | PEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $2 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | PEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $2 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | PEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $2 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | PEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $1 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | PEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | PEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | PEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR | 2019 |
| 2019-08-01 | Merck Sharp & Dohme LLC | $142,863 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-07-31 | Novo Nordisk AS | $72 | Research payment | In-kind items and services | NN9931-4296 | 2019 | |
| 2019-07-30 | Novo Nordisk AS | $2,389 | Research payment | Cash or cash equivalent | EX9536-4388 | 2019 | |
| 2019-07-30 | Novo Nordisk AS | $1,985 | Research payment | Cash or cash equivalent | NN9931-4296 | 2019 | |
| 2019-07-30 | Insulet Corporation | $704 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (10 payments) | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2019 | |
| 2019-07-30 | Novo Nordisk AS | $634 | Research payment | Cash or cash equivalent | NN9931-4296 | 2019 | |
| 2019-07-29 | EMD Millipore Corporation | $31 | Royalty or License | Cash or cash equivalent | Device, DIAGNOSTIC TESTING | 2019 | |
| 2019-07-29 | EMD Millipore Corporation | $28 | Royalty or License | Cash or cash equivalent | Device, DIAGNOSTIC TESTING | 2019 | |
| 2019-07-17 | B. Braun Medical Inc. | $30,000 | Charitable Contribution | Cash or cash equivalent | 2019 | ||
| 2019-07-16 | Novo Nordisk AS | $3,247 | Research payment | Cash or cash equivalent | NN9931-4296 | 2019 | |
| 2019-07-16 | Zimmer Biomet Holdings, Inc. | $3,000 | Grant | Cash or cash equivalent | CMF Non Device, CMF & Thoracic | 2019 | |
| 2019-07-16 | Stryker Corporation | $191 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-16 | Stryker Corporation | $59 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-16 | Stryker Corporation | $36 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-16 | Stryker Corporation | $19 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-11 | OpGen, Inc. | $37,375 | Research payment | Cash or cash equivalent | Acutias AMR Gene Panel Urine Clinical Performance Evaluation | 2019 | |
| 2019-07-11 | CSL Behring | $2,849 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-07-10 | Insulet Corporation | $352 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (10 payments) | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2019 | |
| 2019-07-09 | Medline Industries LP | $4,400 | Charitable Contribution | Cash or cash equivalent | 2019 | ||
| 2019-07-09 | KARL STORZ Endoscopy-America | $270 | Gift | In-kind items and services | LIGHT CABLE, 3.5MM X 300CM. LGTH 9.8 FT Device, VIDEOIMAGING | 2019 | |
| 2019-07-02 | Novo Nordisk AS | $3,247 | Research payment | Cash or cash equivalent | NN9931-4296 | 2019 | |
| 2019-07-02 | Novo Nordisk AS | $1,140 | Research payment | Cash or cash equivalent | NN9931-4296 | 2019 | |
| 2019-07-02 | Novo Nordisk AS | $1,000 | Research payment | Cash or cash equivalent | NN9931-4296 | 2019 | |
| 2019-06-30 | Novo Nordisk AS | $72 | Research payment | In-kind items and services | NN9931-4296 | 2019 | |
| 2019-06-28 | Advanced Respiratory, Inc | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | The MetaNeb System Device, Airway Clearance Device | 2019 | |
| 2019-06-28 | KARL STORZ Endoscopy-America | $450 | Gift | In-kind items and services | TELESCOPE,HOPKINS II,AUTOCLAV, Device, UROLOGY | 2019 | |
| 2019-06-28 | KARL STORZ Endoscopy-America | $420 | Gift | In-kind items and services | LIGHT CABLE, 3.5MM X 300CM. LGTH 9.8 FT Device, VIDEOIMAGING | 2019 | |
| 2019-06-26 | Medtronic MiniMed, Inc. | $18,036 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Minimed 670G System Device, Durable Pump | 2019 | |
| 2019-06-25 | Novo Nordisk AS | $1,754 | Research payment | Cash or cash equivalent | NN9931-4296 | 2019 | |
| 2019-06-25 | BioFire Diagnostics, LLC | $1,500 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray BJI Pivotal Study | 2019 |
| 2019-06-25 | BioFire Diagnostics, LLC | $1,500 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray BJI Pivotal Study | 2019 |
| 2019-06-11 | CSL Behring | $13,367 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-06-11 | CSL Behring | $600 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-06-10 | CSL Behring | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-06-06 | BioFire Diagnostics, LLC | $275 | Food and Beverage (10 payments) | In-kind items and services | Device, Clinical Diagnostics | 2019 | |
| 2019-06-05 | Novo Nordisk AS | $24 | Research payment | In-kind items and services | EX9536-4388 | 2019 | |
| 2019-06-05 | Novo Nordisk AS | $6 | Research payment | In-kind items and services | NN9931-4296 | 2019 | |
| 2019-06-03 | Novo Nordisk AS | $174 | Research payment | In-kind items and services | NN9931-4296 | 2019 | |
| 2019-05-31 | Novo Nordisk AS | $72 | Research payment | In-kind items and services | NN9931-4296 | 2019 | |
| 2019-05-30 | Novo Nordisk Inc | $65,000 | Research payment | Cash or cash equivalent | Decade plus,What relationship b/n longterm weight maint, clinical relevance&healthcare utilization? | 2019 | |
| 2019-05-28 | Novo Nordisk AS | $14,365 | Research payment | Cash or cash equivalent | NN9931-4296 | 2019 | |
| 2019-05-28 | Novo Nordisk AS | $5,120 | Research payment | Cash or cash equivalent | EX9536-4388 | 2019 | |
| 2019-05-21 | Roche Diagnostics Corporation | $5,800 | Consulting Fee | Cash or cash equivalent | CD cobas Analyzer Series Device, Centralized Diagnostics | 2019 | |
| 2019-05-15 | Covidien LP | $10,000 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-05-10 | Medtronic USA, Inc. | $2,050 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | MazorX - Renaissance Device, Enabling | 2019 | |
| 2019-05-09 | CSL Behring | $3,368 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-05-09 | Insulet Corporation | $352 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (10 payments) | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2019 | |
| 2019-05-09 | CSL Behring | $300 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-05-08 | Merck Sharp & Dohme LLC | $72 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $72 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $65 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $40 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | PEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $38 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | PEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $35 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $35 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $35 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | PEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $31 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $30 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | PEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $30 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $23 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $21 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $20 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $15 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $12 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $12 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $12 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $10 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $6 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $4 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | PEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $4 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | PEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $3 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | PEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $3 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $2 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | PEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $2 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | PEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $1 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | PEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $1 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | PEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $1 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | PEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-05-08 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-04-30 | Novo Nordisk AS | $72 | Research payment | In-kind items and services | NN9931-4296 | 2019 | |
| 2019-04-25 | Novo Nordisk AS | $6,495 | Research payment | Cash or cash equivalent | NN9931-4296 | 2019 | |
| 2019-04-25 | Novo Nordisk AS | $4,410 | Research payment | Cash or cash equivalent | NN9931-4296 | 2019 | |
| 2019-04-25 | Novo Nordisk AS | $3,420 | Research payment | Cash or cash equivalent | NN9931-4296 | 2019 | |
| 2019-04-17 | Insulet Corporation | $352 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (10 payments) | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2019 | |
| 2019-04-15 | Merck Sharp & Dohme LLC | $17 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-04-12 | Stryker Corporation | $296 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-04-12 | Stryker Corporation | $117 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-04-12 | Stryker Corporation | $34 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-04-12 | Stryker Corporation | $27 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-04-11 | Novo Nordisk AS | $4,000 | Research payment | Cash or cash equivalent | EX9536-4388 | 2019 | |
| 2019-04-11 | Novo Nordisk AS | $1,500 | Research payment | Cash or cash equivalent | EX9536-4388 | 2019 | |
| 2019-04-10 | Insulet Corporation | $1,760 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (10 payments) | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2019 | |
| 2019-04-08 | Merck Sharp & Dohme LLC | $212 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-04-08 | Merck Sharp & Dohme LLC | $205 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-04-08 | Merck Sharp & Dohme LLC | $42 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-04-08 | Merck Sharp & Dohme LLC | $17 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-04-08 | Merck Sharp & Dohme LLC | $13 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy | 2019 |
| 2019-04-01 | Merck Sharp & Dohme LLC | $232,104 | Consulting Fee | Cash or cash equivalent | 2019 |
The latest 200 records of 238.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Pottsville, PA, county Schuylkill County, PA, state Pennsylvania; placed by its city name.
| Measure | Place (city or town) Pottsville, PA | County Schuylkill County, PA | State Pennsylvania |
|---|---|---|---|
| Population B01003 | 13,364 | 143,558 | 13,018,639 |
| Population, 2020 census P1 | 13,346 | 143,049 | 13,002,700 |
| Median age B01002 | 43.4 | 43.7 | 40.9 |
| Under 18 B01001 | 19.8% | 19.9% | 20.4% |
| 65 and over B01001 | 21.5% | 21.1% | 19.5% |
| Households B11001 | 6,001 | 57,988 | 5,274,853 |
| Foreign born B05002 | 1.0% | 2.7% | 7.7% |
| Median household income B19013 | $54,332 | $68,313 | $77,971 |
| Median family income B19113 | $65,065 | $80,961 | $100,262 |
| Per capita income B19301 | $30,888 | $34,954 | $44,355 |
| Poverty rate B17001 | 19.9% | 12.8% | 11.7% |
| Unemployment rate B23025 | 7.2% | 5.6% | 5.3% |
| Civilian labor force B23025 | 6,496 | 68,442 | 6,684,175 |
| Mean commute (minutes) B08013 | 24.3 | 27.3 | 26.3 |
| Bachelor's degree or higher B15003 | 21.9% | 19.9% | 35.2% |
| Housing units B25001 | 6,972 | 67,295 | 5,806,452 |
| Owner-occupied B25003 | 57.1% | 76.1% | 69.3% |
| Renters B25003 | 42.9% | 23.9% | 30.7% |
| Median home value B25077 | $100,500 | $153,000 | $254,500 |
| Median gross rent B25064 | $822 | $876 | $1,209 |
| White, not Hispanic B03002 | 85.6% | 86.2% | 73.0% |
| Black B03002 | 1.8% | 2.6% | 10.3% |
| Hispanic or Latino B03002 | 8.8% | 7.8% | 8.7% |
| Asian B03002 | 0.2% | 0.5% | 3.8% |
| American Indian and Alaska Native B03002 | 0.0% | 0.0% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Pottsville, PA.
Comments